Patients with high body weight are at increased risk of developing atrial fibrillation (AF) or venous thromboembolism (VTE) and are often treated with antithrombotic drugs. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for many indications, but clinicians avoid DOACs in patients with high body weight because of concerns that decreased drug exposure will reduce efficacy. The International Society on Thrombosis and Haemostasis suggests avoiding DOACs in patients with body weight \( \geq 120 \text{ kg} \) or body mass index (BMI) \( > 40 \text{ kg/m}^2 \), or routinely measuring drug-specific levels and continuing treatment only if the level is within the expected range.

Two papers in this edition of the journal provide further insights into the potential use of DOACs in the long-term treatment of patients with extreme body weights. In the first study, Martin and colleagues measured DOAC drug levels in 100 patients with body weight \( \geq 120 \text{ kg} \) or body mass index (BMI) \( > 40 \text{ kg/m}^2 \), or routinely measuring drug-specific levels and continuing treatment only if the level is within the expected range.

In the second paper, Boriani and colleagues from the Thrombolysis In Myocardial Infarction (TIMI) group examined pharmacokinetic, pharmacodynamic, and clinical outcomes according to body weight in 4,328 patients enrolled in the AF-TIMI-48 trial who were randomized to one of two edoxaban dosing regimens (higher dosing regimen: 60 mg once daily, lower dosing regimen: 30 mg once daily; for both regimens the dose was halved if the estimated creatinine clearance was \(<50 \text{ mL/min}, \text{ weight} < 60 \text{ kg} \), or there was concomitant use of a potent P-glycoprotein inhibitor) or warfarin. Drug levels were measured by a chromogenic anti-Xa assay and were compared with expected reference levels as reported in the International Council for Standardization in Hematology 2018 Consensus Document. The participant median age was 58 years, median body weight was 139 kg (minimum [min] 120, maximum [max] 230), and median BMI was 45 kg/m\(^2\) (min 32, max 72). In participants treated with apixaban, 16 of 18 trough levels (89%) and all 19 peak levels were within or above the expected range. In participants treated with rivaroxaban, all 21 trough levels and 32 of 58 peak levels (55%) were within or above the expected range. There was no significant relationship between body weight, BMI, renal function, and drug levels.

In the second paper, Boriani and colleagues from the Thrombolysis In Myocardial Infarction (TIMI) group examined pharmacokinetic, pharmacodynamic, and clinical outcomes according to body weight in 4,328 patients enrolled in the AF-TIMI-48 trial who were randomized to one of two edoxaban dosing regimens (higher dosing regimen: 60 mg once daily, lower dosing regimen: 30 mg once daily; for both regimens the dose was halved if the estimated creatinine clearance was \(<50 \text{ mL/min}, \text{ weight} < 60 \text{ kg} \), or there was concomitant use of a potent P-glycoprotein inhibitor) or warfarin. Drug levels were measured by a chromogenic anti-Xa assay and were compared with expected reference levels as reported in the International Council for Standardization in Hematology 2018 Consensus Document. The participant median age was 58 years, median body weight was 139 kg (minimum [min] 120, maximum [max] 230), and median BMI was 45 kg/m\(^2\) (min 32, max 72). In participants treated with apixaban, 16 of 18 trough levels (89%) and all 19 peak levels were within or above the expected range. In participants treated with rivaroxaban, all 21 trough levels and 32 of 58 peak levels (55%) were within or above the expected range. There was no significant relationship between body weight, BMI, renal function, and drug levels.

The pharmacokinetic results reported by both Martin et al and Boriani et al confirm preliminary data from previous studies that almost all patients with body weight \( > 120 \text{ kg} \) will achieve expected trough drug levels with the use of
apixaban, edoxaban, and rivaroxaban. Most of these patients will also achieve expected peak levels with apixaban but some achieve lower than expected peak levels with the once-daily DOACs, edoxaban, and rivaroxaban. However, lower than expected peak levels did not appear to compromise efficacy; Boriani et al demonstrated consistent benefits with edoxaban compared with warfarin in patients with body weight >120 kg. Similarly, consistent benefits of DOACs have been reported from the ARISTOTLE trial comparing apixaban with warfarin for stroke prevention in patients with AF and body weight >120 kg, as well as in a meta-analysis of AF trials examining outcomes with DOACs compared with warfarin according to BMI.

Despite the overall reassuring results from the analyses by Martin et al and Boriani et al with the use of DOACs in patients with high body weights, several caveats should be considered. First, drug levels are poorly validated as a surrogate for clinical outcomes. Although it is possible to accurately measure DOAC drug levels, patient characteristics (e.g., age, renal function) confound the association with clinical outcome, a single measurement of drug levels is unreliable, and optimal drugs remain to be established. Second, event rates for both thromboembolism and bleeding are low in patients with high body weights, and this limits the power to detect clinically important treatment interactions. Third, despite representing two of the larger studies on this topic, the reports by Martin et al and Boriani et al collectively included very few patients with body weight >150 kg and clinical outcome data for this extreme weight group remain limited.

What are the implications of these findings for clinical practice? We believe that there is an urgent need for revision of the guidelines concerning the use of DOACs in patients with high body weights. We suggest that updated guidelines should recommend DOACs in preference to warfarin for patients with AF or VTE and body weights up to 150 kg without routine measurement of drug levels (Fig. 1). Whether DOACs should also be preferred in patients with body weights above 150 kg remains an open question, but we suspect that even in these patients the greater convenience of DOACs will make them an attractive option. At the other end of the weight spectrum, DOACs should likely also be preferred because patients with low body weight not only are at higher risk of thromboembolism than patients with middle or high body weights, but also appear to derive greater benefits of treatment with a DOAC. At the same time, body weights should not be considered in isolation, but should be incorporated as part of an integrated approach to patient care.

What are the implications for future research? Despite the advances to date, we echo Boriani and colleagues in calling for additional randomized outcome data in patients at the greatest extremes of body weight (<35 or >150 kg). We encourage ongoing and future trials of DOACs to actively enroll patients with extremes of body weights, and to consider routine measurement of steady-state trough and peak levels in at least a subset of these patients. In the meantime, additional information on the efficacy and safety of DOACs compared with warfarin in AF in patients at extremes of body weight is expected from an ongoing collaborative meta-analysis of the phase 3 randomized controlled trials in patients with AF.

Conflict of Interest

J.W.E. reports honoraria and grant support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb/Pfizer, Daiichi Sankyo, Glaxo Smith Kline, Janssen,
sanofi aventis and Eli Lilly as well as a personnel award from the Heart and Stroke Foundation.

References